Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to provide open label emtricitabine/tenofovir disoproxil
fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study
GS-US-203-0107.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir